Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Selling, General & Admin	64.91	57.05	1.29	1.53	1.73	1.58
Research & Development	0.19	0.22	0.25	0.25	0.26	0.23
Total Operating Expenses	65.1	57.28	1.54	1.78	1.99	1.81
Operating Income	-65.1	-57.28	-1.54	-1.78	-1.99	-1.81
Interest Income	0	0	0	0	0.01	0
Interest Expense	-0.72	-0.56	-0.67	-0.53	-0.57	-0.45
Other Non-Operating Income (Expense)	-0.24	-1.08	0.25	-0.48	-0.16	0.12
Total Non-Operating Income (Expense)	-0.97	-1.65	-0.41	-1.01	-0.72	-0.33
Pretax Income	-66.07	-58.92	-1.95	-2.79	-2.71	-2.14
Provision for Income Taxes	-	-	-0.13	-0.13	-0.05	-0.11
Net Income	-67	-58.92	-2.01	-3.13	-3.36	-2.42
Net Income Attributable to Preferred Dividends	0.93	-	0.19	0.47	0.7	0.39
Net Income to Common	-67	-58.92	-2.01	-3.13	-3.36	-2.42
Shares Outstanding (Basic)	10	4	0	0	0	0
Shares Outstanding (Diluted)	10	4	0	0	0	0
Shares Change (YoY)	147058.48%	279940.65%	4789.57%	2448.85%	2149.51%	12210.68%
EPS (Basic)	10.58	-14.85	-1420.53	-108000.00	-2953800.00	-48000000.00
EPS (Diluted)	10.58	-14.85	-1420.53	-108000.00	-2953800.00	-48000000.00
EPS Growth	-99.06%	-	-	-	-	-
Shares Outstanding	12.85	3.97	0.01	0	0	-
Free Cash Flow	-3.11	-0.41	-0.94	-1.11	-1.44	-1.15
Free Cash Flow Per Share	-0.30	-0.10	-659.93	-38138.36	-1263258.62	-22658961.98
EBITDA	-65.1	-57.28	-1.54	-1.77	-1.99	-1.81
EBIT	-65.1	-57.28	-1.54	-1.78	-1.99	-1.81
Effective Tax Rate	-	0.00%	6.62%	4.65%	2.03%	5.30%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.